February 9, 2017 06:02 AM EST

Acorda preps FDA filing after Parkinson’s drug hits the primary endpoint in PhIII

John Carroll

Editor & Founder

Acorda’s $525 million gamble on a Phase III Parkinson’s drug has paid off. The biotech $ACOR announced early Thursday that the late-stage study of an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Acorda preps FDA filing after Parkinson’s drug hits the primary endpoint in PhIII

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Acor­da preps FDA fil­ing af­ter Parkin­son’s drug hits the pri­ma­ry end­point in PhI­II

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Acorda preps FDA filing after Parkinson’s drug hits the primary endpoint in PhIII

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy